Lastest Report on Systemic Lupus Erythematosus Market (SLE)

1
Frontier Pharma Systemic Lupus Erythematosus
Identifying and Commercializing First-in-Class
InnovationbyMarketsandMarkets

• Explore all reports for Autoimmune Drugs 
  market
• _at_
• http//www.rnrmarketresearch.com/reports/life-scie
  nces/pharmaceuticals/diseases-treatment/autoimmune
  -drugs .

2
Frontier Pharma Systemic Lupus Erythematosus
Identifying and Commercializing First-in-Class
Innovation

• The Systemic Lupus Erythematosus (SLE) drug
  market is currently under-served by non-generic,
  targeted therapies. Whilst the only Food and Drug
  Administration (FDA)-approved biologic, Benlysta
  (belimumab), generated sales of 111m in 2012,
  there is little evidence that the drugs
  performance is significantly superior to other
  B-cell targeted therapies such as Rituxan
  (rituximab), which is often used off-license to
  treat refractory SLE patients. Therapeutics
  entering the market therefore do not face the
  staggering level of competition from currently
  marketed programs as in other markets such as the
  Rheumatoid Arthritis (RA) market. Emerging market
  entrants that appear to offer significant
  therapeutic benefits are likely to cause dramatic
  changes to the market landscape.
• A growing understanding of the signaling pathways
  underlying SLE pathophysiology including, but not
  limited to, B cells, T cells and intracellular
  kinases, is translating into a higher number of
  novel, and more importantly, first-in-class
  targeted therapeutics entering the developmental
  pipeline. In particular, a high level of
  investment in the development of
  cytokine-blocking strategies is evident, as
  therapies targeting the interferon pathway are
  relatively common in the pipeline.
• Request a Sample _at_ http//www.rnrmarketresearch.co
  m/contacts/request-sample?rname145685 .

3
Frontier Pharma Systemic Lupus Erythematosus
Identifying and Commercializing First-in-Class
Innovation

• Scope
• The report analyzes the market for SLE
  therapeutics and the pipeline products in that
  market, with particular emphasis on
  first-in-class programs.
• A brief introduction to SLE, including symptoms,
  pathophysiology, disease scoring indices and
  overview of pharmacotherapy
• In-depth analysis and literature review on
  marketed products, including analyses of their
  safety, efficacy, treatment patterns and
  strengths/weaknesses, based on published clinical
  trials, as well as a reference table of drugs in
  terms of safety and efficacy
• Overview of how innovation products are
  contributing to the market for SLE therapeutics
• Comprehensive review of the pipeline for
  first-in-class therapies, which is analyzed on
  the basis of phase distribution, molecule types
  and molecular targets, as well as administration
  routes
• Complete report spread across 89 pages available
  _at_ http//www.rnrmarketresearch.com/frontier-pharma
  -systemic-lupus-erythematosus-identifying-and-comm
  ercializing-first-in-class-innovation-market-repor
  t.html .

4
Frontier Pharma Systemic Lupus Erythematosus
Identifying and Commercializing First-in-Class
Innovation

• Reasons to buy
• The report will assist the business development
  strategies of companies that wish to develop
  novel therapies with improved benefits to
  existing treatments. It will also be of interest
  to companies seeking to expand their pipeline
  portfolio through licensing agreements and
  co-development deals. It will also allow you to
• Understand the SLE pipeline and the factors which
  indicate that it is becoming more innovative
• Understand the overall focal shifts in
  therapeutic molecular targets for the treatment
  of SLE
• Understand the distribution of the pipeline
  programs by phase of development, molecule type
  and molecular target
• Identify the list of first-in-class programs that
  are potentially open to deal-making opportunities
• Inquire For Discount _at_ http//www.rnrmarketresearc
  h.com/contacts/discount?rname145685 .

5
Frontier Pharma Systemic Lupus Erythematosus
Identifying and Commercializing First-in-Class
Innovation

• Few Points of Table Of Content-
• Systemic Lupus Erythematosus 93.1 Disease
  Overview 93.2 Epidemiology 93.3 Disease
  Pathophysiology 103.4 Disease Symptoms 103.5
  Environmental and Genetic Predisposition 113.6
  Diagnosis 113.7 Disease Severity Assessments
  123.7.1 PGA 123.7.2 SLEDAI 123.7.3 BILAG
  133.7.4 SRI 133.8 Lupus Nephritis 133.9
  Pharmacotherapy Algorithm 14

6
Frontier Pharma Systemic Lupus Erythematosus
Identifying and Commercializing First-in-Class
Innovation

• Related Market Reports
• Orencia (Systemic Lupus Erythematosus and Lupus
  Nephritis) Forecast and Market Analysis to 2022
• Rituxan (Systemic Lupus Erythematosus and Lupus
  Nephritis) Forecast and Market Analysis to 2022
• Chronic Cutaneous Lupus Erythematosus (CCLE) /
  Discoid Lupus Erythematosus (DLE) Pipeline
  Review, H1 2013
• Lupus Erythematosus Pipeline Review, H1 2013
• PharmaPoint Systemic Lupus Erythematosus and
  Lupus Nephritis Current and Future Players

7
Frontier Pharma Systemic Lupus Erythematosus
Identifying and Commercializing First-in-Class
Innovation

• For more details contact Mr. Priyank Tiwari
  sales_at_rnrmarketresearch.com / 18883915441

RnR Market Research RnRMarketResearch.com, an
online repository of market  research reports,
offers in-depth analysis of over 5000 market
segments. RnR  Market Research library has
syndicated reports by leading market research 
publishers across the globe.